Skip to content

Study · Not a test of the peptide alone · 2020

4 results

A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs.

Maikawa CL, Smith AAA, Zou L, Roth GA, Gale EC, Stapleton LM, Baker SW, Mann JL, Yu AC, Correa S, Grosskopf AK, Liong CS and 7 more

Show all authors

Meis CM, Chan D, Troxell M, Maahs DM, Buckingham BA, Webber MJ, Appel EA

Nature biomedical engineering11 May 2020Cited by 51 (Europe PMC)

PMID32393892 (opens in a new tab)PMCIDPMC7274092 (opens in a new tab)DOI10.1038/s41551-020-0555-4 (opens in a new tab)PepBankPUB-32393892
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 01AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Pharmacokinetics

    In diabetic pigs, supramolecular modification improved the pharmacokinetics of insulin-and-pramlintide therapy.

    In plain wordsIn pigs with diabetes, supramolecular modification improved the pharmacokinetics of insulin-and-pramlintide therapy.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableDual-hormone pharmacokinetics
    Study

    pign: not reported in source

    Diabetic pigs
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Here, we show that the supramolecular modification of insulin and pramlintide with cucurbit[7]uril-conjugated polyethylene glycol improves the pharmacokinetics of the dual-hormone therapy and enhances postprandial glucagon suppression in diabetic pigs.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 02AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Efficacy outcome

    In diabetic pigs, supramolecularly modified insulin-and-pramlintide enhanced postprandial glucagon suppression.

    In plain wordsIn pigs with diabetes, supramolecularly modified insulin-and-pramlintide increased glucagon suppression after meals.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial glucagon suppression
    Study

    pign: not reported in source

    Diabetic pigs
    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    Here, we show that the supramolecular modification of insulin and pramlintide with cucurbit[7]uril-conjugated polyethylene glycol improves the pharmacokinetics of the dual-hormone therapy and enhances postprandial glucagon suppression in diabetic pigs.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  3. 03AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Pharmacokinetics

    In diabetic rats, stabilized insulin-and-pramlintide co-formulation increased overlap of the hormone pharmacokinetic curves compared with separate administration.

    In plain wordsIn rats with diabetes, stabilized insulin-and-pramlintide co-formulation increased overlap of the hormone pharmacokinetic curves compared with separate administration.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreasePharmacokinetic curve overlap
    Study

    ratn: not reported in source

    Diabetic rats
    Comparator
    Separate hormone administration
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    In diabetic rats, the administration of the stabilized co-formulation increased the area-of-overlap ratio of the pharmacokinetic curves of pramlintide and insulin from 0.4 ± 0.2 to 0.7 ± 0.1 (mean ± s.d.) for the separate administration of the hormones.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  4. 04LabNot a test of Pramlintide (Symlin) aloneIn vitro (cell-free)Other

    In lab tests, the co-formulation remained stable for over 100 h, whereas commercial insulin analogue formulations aggregated after 10 h.

    In plain wordsIn lab tests, the co-formulation remained stable for over 100 h, whereas commercial insulin analogue formulations aggregated after 10 h.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseFormulation stability
    Study

    n: not reported in source

    Co-formulation under continuous agitation at 37 °C
    Comparator
    Commercial insulin analogue formulations
    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    The co-formulation is stable for over 100 h at 37 °C under continuous agitation, whereas commercial formulations of insulin analogues aggregate after 10 h under similar conditions.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.